Association of Antipsychotic Use With Hospital Events and Mortality Among Medicare Beneficiaries Residing in Long-Term Care Facilities by Simoni-Wastila, Linda et al.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2009
Association of Antipsychotic Use With Hospital
Events and Mortality Among Medicare
Beneficiaries Residing in Long-Term Care Facilities
Linda Simoni-Wastila
Priscilla T. Ryder
Butler University, pryder@butler.edu
Jingjing Qian
Ilene H. Zuckermann
Thomas Shaffer
See next page for additional authors
Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Geriatrics Commons, Pharmaceutics and Drug Design Commons, and the Psychiatric
and Mental Health Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Simoni-Wastila, Linda; Ryder, Priscilla T.; Qian, Jingjing; Zuckermann, Ilene H.; Shaffer, Thomas; and Zhao, Lirong, "Association of
Antipsychotic Use With Hospital Events and Mortality Among Medicare Beneficiaries Residing in Long-Term Care Facilities" (2009).
Scholarship and Professional Work – COPHS. Paper 82.
http://digitalcommons.butler.edu/cophs_papers/82
Authors
Linda Simoni-Wastila, Priscilla T. Ryder, Jingjing Qian, Ilene H. Zuckermann, Thomas Shaffer, and Lirong
Zhao
This article is available at Digital Commons @ Butler University: http://digitalcommons.butler.edu/cophs_papers/82
Association of Antipsychotic Use With Hospital Events and
Mortality Among Medicare Beneficiaries Residing in Long-Term
Care Facilities
Linda Simoni-Wastila, R.Ph., Ph.D., Priscilla T. Ryder, M.P.H., Ph.D., Jingjing Qian, M.S.,
Ilene H. Zuckerman, Pharm.D., Ph.D., Thomas Shaffer, M.H.S., and Lirong Zhao, M.S.
Department of Pharmaceutical Health Services Research, Peter Lamy Center on Drug Therapy
and Aging, University of Maryland School of Pharmacy, Baltimore, MD (LS-W, PTR, JQ, LHZ, TS,
LZ)
Abstract
Objective—Antipsychotic (AP) utilization has grown significantly in long-term care (LTC)
settings. Although a growing literature associates AP use with higher mortality in elderly with
dementia, the association of APs with hospital events is unclear. The authors examine prevalence
and trends in AP use by Medicare beneficiaries residing in LTC and the association of APs and
other drug use variables with hospital events and mortality.
Design—Retrospective analysis using sequential multivariate Cox proportional hazards models.
Setting—Medicare Current Beneficiary Survey linked to Institutional Drug Administration and
Minimum Data Set files.
Participants—A total of 2,363 LTC Medicare beneficiaries, 1999–2002.
Measurements—Trends in LTC AP use overall and by type and duplicative use; association of
AP utilization and two outcomes: hospital events and all-cause mortality.
Results—AP use rose markedly from 1999 to 2002 (26.4%–35.9%), predominantly due to
increased use of atypical agents. After controlling for sociodemographic and clinical factors, AP
use is not related to hospital events (hazard ratio [HR] = 0.98, 95% confidence interval [CI] =
0.82–1.63 p = 0.7951). AP use is associated with reduced mortality in unadjusted and intermediate
models, but loss of significance in the final model (HR = 0.83, 95% CI = 0.69–1.00, p = 0.0537)
suggests that disease and drug burden factors may confound the AP-mortality relationship.
Conclusion—This study provides no evidence of increased hospital events or mortality in LTC
residents who use AP medications. Findings contribute to a growing body of evidence that APs,
particularly atypical agents, may be associated with reduced mortality in LTC residents.
Keywords
Antipsychotic medications; long-term care; medicare beneficiaries; drug trends
Use of antipsychotic (AP) medications in long-term care (LTC) has grown significantly over
the past decade.1,2 A primary driver of increased use is the shift from older first generation
agents, such as haloperidol and perphenazine, to the newer atypical agents (risperidone,
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olanzapine, aripiprazole, ziprasidone, and quetiapine).2,3 Despite the marked rise in the use
of this therapeutic class, there is little information on the prevalence, appropriateness, or
outcomes associated with AP prescribing in LTC residents. Further, the evidence that is
available is contradictory or inconclusive, leaving patients and their providers unable to
make sound medication choices.
In the spring of 2005, concerns about the safety of atypical APs led the U.S. Food and Drug
Administration to issue a black box warning against their use in treating elderly patients
with dementia.4 It is estimated that approximately half of newly admitted nursing home
residents have dementia, and estimates of dementia prevalence among all residents range
from 40% to 75%.5 APs are frequently used in this setting for behavioral disturbances that
may accompany dementia, such as aggression and agitation6; however, such use is generally
considered outside the U.S. Food and Drug Administration-approved indications.7
In a large study of Pennsylvania retirees using administrative claims data conducted by
Wang et al.,8 AP use by nursing home residents was associated with increased risk of
mortality, although the risk was slightly lower than that of community-dwelling elders.
Moreover, another population-based, retrospective cohort study, conducted by Rochon et
al.,9 compared short-term serious events (acute care hospital admission or death) after initial
AP use between older adults with dementia in community-dwelling and nursing home in
Canada. Results from this study showed that patients who received conventional AP therapy
were a little more likely to develop any serious event during the 30 days of follow-up. The
pattern of serious events was similar but less pronounced among older adults living in a
nursing home. However, other research evaluating the impact of APs on adverse outcomes
in the LTC-residing older adults have produced mixed results due to differences in data
source, methodological approach, sample size, and geographic variation in treatment
practices. For instance, although some studies8,10 discerned a positive association between
AP use and mortality, especially in the use of conventional agents, other studies report that
APs seem to have either no effect—or even a protective effect—on mortality.11
A similar mix of findings is reported when examining hospitalization associated with AP
use.11,12 In a sample of geriatric patients admitted to a psychiatric center, Barak et al.12
found no association between hospitalization and class of AP, whereas Raivio et al.11 found
a lower mean number of hospital admissions among elderly institutionalized dementia using
APs relative to non-AP users, regardless of AP class. Yet another study found increased risk
for hospitalization for adverse cardiac effects among conventional AP users only.13 Finally,
the somewhat larger literature examining the association of AP use and adverse outcomes in
the community-dwelling older adult population also fail to discern clear-cut findings of
risk.8,12,14–19
Conclusions from these studies are further complicated by their focus on individuals with
dementia and on specific APs or AP class (i.e., conventional versus atypical). Although
several studies have examined the association between AP use and older adults with
dementia9,17,18,20,21 and without,8,14,19 findings were not definitive. Furthermore, there is
no clear association between mortality and type of AP, regardless of dementia status.
Although some studies have found higher mortality associated with conventional APs,9,14,15
others have found statistically and clinically important associations with atypical
agents.8,10,15,18
Despite the prevalence of AP use in LTC residents, there is a paucity of studies in this
population. Such studies are necessary as LTC residents typically reflect radically different
care and medication prescribing patterns than their community-dwelling counterparts. These
few studies are limited in that they generally utilize small sample sizes, reflecting single or a
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small number of homes, and are conducted in other countries, thereby limiting
generalizability to the U.S. population.9,11,20,21 Although three studies that include a subset
of LTC residents use large databases,8,9,13 both also are limited geographically.
This study examines the utilization of APs in LTC facilities in the United States. Using a
national sample of Medicare beneficiaries residing in LTC facilities, we provide national
estimates of the prevalence of and trends in use of APs from 1999 to 2002. We further
investigate the association of AP use with hospital events and mortality, controlling for
sociodemographics, clinical indicators, and other key covariates.
METHODS
Data Source
This study is a retrospective analysis of the 1999–2002 Medicare Current Beneficiary
Survey (MCBS) Cost and Use Surveys. The MCBS is a continuous sample of U.S. Medicare
beneficiaries that employs a panel design in which beneficiaries are surveyed three times
annually for a maximum of 4 years.22 Beneficiaries may live in the community or in LTC
facilities. For the purposes of this study, the designation “LTC” includes both skilled nursing
facilities and other congregate care settings, such as “high end” assisted living facilities,
which receive Medicare reimbursement, provide round-the-clock skilled nursing, and have
centralized medication distribution. For the purposes of this analysis, we excluded
beneficiaries residing in psychiatric facilities (n = 20).
The MCBS contains information on sociodemographics and medical services used. These
files were augmented with information from Institutional Drug Administration files and
extracts from the Minimum Data Sets for LTC residents. The Institutional Drug
Administration file contains information abstracted monthly Medication Administration
Records and includes names and frequency of administration of all medications. Only drugs
actually administered are included in analysis.
To maximize sample size, data are arranged as annual crosssections for all 4 years and
concatenated. For individuals included in multiple data years, one observation year was
randomly chosen. Additional inclusion criteria include maintaining individuals with at least
one Medication Administration Record and one Minimum Data Set record. The final
analytic sample consists of 2,363 unique individuals identified as staying in an LTC facility
at least 1 day during the study year.
Measures
We created a binary variable to measure administration of any AP medication in the first 6
months of the study year. We further differentiated AP use by atypical (i.e., clozapine,
risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) and conventional status.
We also flagged duplicative AP use, operationalized as the use of two or more unique APs
used concomitantly for 2 or more months. This measure excludes occasional use of APs
(i.e., acute pro re nata use), as well as minimizes duplicative use likely due to titration and/or
switching APs. For those patients using both atypical and conventional APs, we grouped
them into atypical users.
Outcomes in this investigation are acute hospital events and all-cause mortality. Time to
outcome event is defined as days from the first day of recorded AP exposure to the first
outcome event occurring within the calendar year. This “exposure to event” time period has
been used in other studies.8,10 “Hospital event” is defined as transfer from a LTC facility to
an inpatient hospital stay or emergency department visit. We consider only the first hospital
event in analysis. Mortality is determined from Medicare enrollment eligibility files.
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Sociodemographic variables include age, sex, race, marital status, geographic region of
residence, income, and education. Health-related variables include count of reported
physical conditions, mental health disorders, anxiety, mood disorders, schizophrenia/
psychotic disorders, signs and symptoms (delusions and delirium), medical and prescription
drug insurance status, self-rated health, limitations in activities of daily living (ADL), body
mass index, and physical restraint use. We also constructed a variable measuring
psychoactive drug burden, operationalized as a count of all unique, non-AP
psychotherapeutic drug classes administered within the study year.
Data Analysis
We use Wald χ2 tests and t-tests to compare AP users and nonusers, as well as atypical
versus conventional AP users. Multiple Cox proportional hazards models are applied to
estimate time from AP exposure to death or hospital event, controlling for covariates.
Starting with an unadjusted proportional hazards model, we use a model building approach
that sequentially adds groups of related variables. Next, we add demographic variables,
socioeconomic characteristics, and observation year, followed by a third model adding
general health-related variables and use of physical restraints. The final model further
includes disease and drug burden variables. Assumptions of proportional hazards were
tested and verified by plotting the log-log survivor functions for AP users and nonusers for
each outcome, with resulting curves being roughly parallel for both AP users and nonusers.
We report both p values and associated 95% confidence intervals. For categorical
explanatory variables with two or more categories, we will report group χ2 in text and
individual category χ2 in the tables. For trend analyses, we report the Cochrane-Armitage
test for trend. All analyses relied on SAS statistical software, version 9.1 (SAS, Cary, NC).
Institutional Review Board’s Approval and Funding
This investigation was deemed exempt by the University of Maryland, Baltimore
Institutional Review Board, as the analysis relied on a limited dataset. This study was
funded by a contract with the Centers for Medicare and Medicaid Services (CMS). The
funding source collaborated in forming the research questions but not in study design or
analysis. Preliminary analyses upon which this publication is based were performed under
Contract Number HHSP23320044302EC entitled “Impact of Antipsychotic Use on Hospital
Event and Mortality in Medicare Beneficiaries Residing in Long-Term Care Facilities,”
sponsored by the CMS, Department of Health and Human Services. The content of this
publication does not necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government. The authors assume full
responsibility for the accuracy and completeness of the ideas presented.
RESULTS
Characteristics of the Sample
Table 1 summarizes the characteristics of AP users and nonusers. During the study period (6
months of follow-up during the years 1999–2002), almost one third of residents received at
least one AP medication. Nearly one third of residents experienced at least one hospital
event and more than a quarter died within the follow-up period. In bivariate analysis, the use
of APs was not significantly associated with hospital events; however, mortality was
significantly lower among AP users than AP nonusers. AP users were younger, more often
male, and less often married than nonusers. AP users also had fewer ADL limitations, and
reported greater prevalence of anxiety, schizophrenia, mood disorders, delirium, and
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delusion than nonusers. AP users also more often used other psychotherapeutic medication
classes, including antidepressants, mood stabilizers, and anxiolytics.
Although not reported in tabular form, subanalyses found that of the 742 residents who
received APs, 456 (61.5%) were administered only atypicals, 194 (26.2%) received only
conventional medications, and 92 (12.4%) used both AP classes. Relative to conventional
AP users, atypical AP users were more often white (86.9% versus 79.9%, χ2 = 5.46, df = 1,
p = 0.0194), more often used mood stabilizers (28.7% versus 16.0%, χ2 = 12.16, df = 1, p =
0.0005) and anxiolytics (50.2% versus 39.7%, χ2 = 6.33, df = 1, p = 0.0119), and reported
more comorbid conditions (6.8 [SD = 4.14] versus 6.0 [SD = 4.14], t = −2.39, df = 740, p =
0.0172).
Prevalence and Trends in AP Use
AP use by Medicare beneficiaries residing in LTC facilities rose markedly during the 4-year
period spanning 1999–2002 (Fig. 1). The use of any AP increased from 26.4% in 1999 to
35.9% in 2002 (Cochrane-Armitage test for trend, z = −3.99, p <0.0001), indicating
increasing proportions of beneficiaries with any AP use. Increased use of the atypical agents
dominated much of this trend, with atypical use more than doubling from 13.9% in 1999 to
31.6% in 2002 (Cochrane-Armitage test for trend, z = −7.98, p <0.0001). Conventional AP
use decreased by about half, from 15.9% to 8.4% (Cochrane-Armitage test for trend, z
=4.33, p <0.0001). Duplicative AP use increased from 2.1% of AP users in 1999 to 4.5% by
2002 (Cochrane-Armitage test for trend, z = −2.41, p = 0.0159).
Association of AP Use on Hospital Events and Mortality
Table 2 shows findings from the Cox proportional hazards models of the association
between any AP use and hospital events and mortality. Although AP use showed an inverse
relationship with mortality in unadjusted and partially adjusted models, the association
failed to maintain statistical significance in the final, fully adjusted model. Use of any AP
did not reach statistical significance for hospital events in any model.
Other explanatory variables are associated with our outcomes of interest. We only comment
on those factors found to be statistically significant in the final adjusted models. Additional
factors positively associated with hospital events included ADL impairment and increasing
numbers of comorbidities, whereas other positive correlates of mortality included male sex,
reporting fair or poor health, presence of delirium, 85 and older age group, being
underweight, and observation year.
Possession of supplemental health insurance seemed to have a protective effect on the risk
of incurring a hospital event. Diagnosis of a mood disorder and urban residence also
shortened the time to a hospital event, whereas age less than 65 and a diagnosis of
schizophrenia were associated with lower mortality.
We performed analyses stratified by AP type, age group (<65 versus those 65 and older),
type of LTC residence (skilled nursing facility versus other site types), and dementia status
(Table 3). We found no statistically significant differences in hospital events for any of these
stratified analyses. Mortality, however, was inversely associated with the use of atypical
APs only. Reduced mortality also was associated with use of any AP among residents living
in nursing homes (relative to other types of LTC), beneficiaries with dementia, and
beneficiaries aged 65 years and older.
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CONCLUSIONS
This is the first study to document the association of AP use, as well as the differential
influence of atypical AP use, with mortality and hospital events in a national LTC
population while controlling for important sociodemographic, economic, and clinical
characteristics. It furthers previous work examining the quality of AP prescribing conducted
by the researchers by updating national estimates and patterns of AP use.23 We find AP use
highly prevalent in LTC facilities, with 35.9% of LTC Medicare beneficiaries administered
at least one AP in 2002. Although this estimate is somewhat higher than that estimated in a
recent study by Kamble et al.2; however, that study used a 1-day cross-sectional capture of
medications and was restricted to a nursing home population.
Contrary to research that finds a positive association between AP use and mortality (relative
to no AP use),8,10,17,18 our study suggests that use of APs, regardless of AP class, appears
not to increase mortality risk among Medicare beneficiaries residing in LTC facilities. This
possibility is consistent with findings from other studies of institutionalized patients with
dementia.11,21 Indeed, our study suggests that use of any AP is associated with reduced
hazard of mortality in unadjusted and partially adjusted models that do not control for
disease and drug burden (Table 2). However, we do find significant, inverse associations
between AP use and mortality in our fully adjusted stratified analyses of beneficiaries
residing in nursing homes relative to other facilities, beneficiaries diagnosed with dementia
relative to nondementia, and beneficiaries aged 65 years and older (Table 3).
We suspect that this study’s inclusion of appropriate diagnostic information, as well as
controlling for drug burden, health status, and markers of functional status (e.g., inclusion of
ADLs), and other patient-level information not commonly available in administrative claims
data eliminates much of the heterogeneity between AP users versus nonusers. In other
words, it explains differences in both medical conditions and the severity of these conditions
that might otherwise be attributable to the APs and/or the psychotic disorders themselves.
Prior investigations of LTC populations have used various strategies to control for the
important potential confounders of comorbidity and severity-of-illness, such as behavior
disturbance, drug burden, functional limitations, and use of physical restraints.9–11,13,24 No
previously conducted study has successfully controlled for all of these factors. For example,
a study by Hollis et al.24 inferred comorbidity from prescription drug claims data and was,
therefore, unable to measure factors beyond overall morbidity and drug burden. Gill et al.10
and Rochon et al.9 used propensity scores for comorbidity and drug burden, whereas
Liperoti et al.13 controlled for several health-related factors (behavior problems, functional
status, body mass index, concomitant medications, and comorbidity) using information from
the Systematic Assessment of Geriatric Drug Use via Epidemiology database. In another
secondary analysis,11 a range of health-related covariates, including restraint use, ADL
dependence, number of medications used, and comorbidity (measured using the Charlson
comorbidity index, which assesses risk of 1-year mortality) were directly assessed, finding
(as does our study) that neither atypical nor conventional AP use leads to increased
hospitalization or mortality.
When contrasting the use of atypical and conventional APs (Table 3), we find no significant
differences for hospital events. However, our findings do suggest that atypical agents may
reduce the risk of mortality in this population. The three studies that note a positive
association of conventional AP use to adverse outcomes also find a positive and clinically
important association with atypical agents.8–10 Consonant with our results, at least one study
of elderly institutionalized dementia patients finds lower mortality among atypical users
compared with nonusers.11
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Our study results may differ from previous studies for several reasons, including those noted
above. For one, we explicitly control for many sociodemographic, health-related,
comorbidity, and drug burden characteristics that other studies, because of data availability
issues, do not. This difference is bolstered by our finding that although unadjusted analyses
find an association between mortality and AP use (but not hospital events); the relationship
becomes attenuated with adjustment for disease and drug covariates. Indeed, in the study
most closely resembling ours,10 sensitivity analysis suggests that unmeasured confounders
(such as general health status, physical functioning, and total medication burden) may
independently increase the risk for death. Although some potential confounders were
included in the propensity score adjustment component of the analyses by Gill et al.10 and
Rochon et al.,9 they differ from the ones we employed and are used differently in analysis.
Another potential limitation is that we examine prevalent, rather than incident, AP use. If
this is the case, examining prevalent use would tend to bias results toward the null. As well,
prior work has found the deleterious effects of AP use strongest shortly after initiation of
treatment.8,9,16,25 For example, Rochon et al.9 defined serious event as within 30 days of
initiating AP therapy, which is different from our outcome definition, the first day of
recorded AP exposure to the first outcome event occurring within the calendar year.
Although it is possible that those residents most susceptible to AP-related mortality could
have died before they could be observed in our analysis (thus weakening the relationship
between AP use and mortality), our finding of decreased mortality risk with AP use suggests
a possible, longer-term protective effect of these agents that requires further investigation.
It is important to note our study focuses on Medicare beneficiaries of all ages; indeed, 17.3%
of our population is composed of individuals less than 65 years of age who qualify for
Medicare on the basis of disability. To address the issue of age, we repeated analysis for
those younger than age 65 and those aged 65 and older and found that although AP use is
not related to hospital events among either age group, there is a significant inverse
association of mortality and AP use among those aged 65 and older. We also were
concerned that AP use in nursing home residents might differ from use by those residing in
other settings, such as assisted living or congregate care facilities. In our study, even in final
adjusted models, mortality remains lower among those nursing home patients using APs, the
group in which we would expect the greatest disease and drug burden. Finally, because
many previous investigations include only patients with dementia,8,9,14,15 we find a positive
significant relationship between AP use and decreased mortality in demented residents. In
this dataset of Medicare beneficiaries residing in LTC, proportionally more people with
dementia live in nursing homes than other types of LTC, so similar results for the two
stratifications are not surprising.
Our dataset has a high representation of skilled nursing facilities and nursing facilities
certified by CMS; therefore our findings may not be fully generalizable to the entire LTC
population. Confidence intervals for our results are moderately wide, which indicates that
our ability to find differences is limited. Diagnoses are not necessarily confirmed through
clinical assessment and therefore may be underreported. Finally, data limitations preclude
the ability to follow subjects farther than the end of a calendar year.
Despite these limitations, this study has notable strengths: it employs a national sample, we
directly control for important sociodemographic and health-related covariates, and it
addresses AP use in a particularly vulnerable population. Further studies examining incident
AP use with longer term follow-up and more current data are needed to determine whether
and which older population groups are at risk for negative health outcomes associated with
AP administration.
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TABLE 2
Cox Proportional Hazards Modelsa for Associations Between Antipsychotic Use and Hospital Events and
Mortality Among Medicare Beneficiaries, 1999–2002 (n = 2,363)
Variable Model I (Unadjusted)
Model II (Model I +
Demographics,
Socioeconomic Status)
Model III (Model II +
Health Variables)
Model IV (Model III +
Disease and Drug
Burden)
I. Hospital Events HR (95%
CI) p
 Antipsychotic use 1.03 (0.88–1.21) 0.6693 1.06 (0.90–1.24) 0.4921 1.04 (0.89–1.22) 0.6436 0.98 (0.82–1.63) 0.7951
 Gender, male 1.09 (0.92–1.29) 0.3052 1.11 (0.94–1.31) 0.2217 1.07 (0.90–1.27) 0.4300
 Age groupb
  <65 years 0.53 (0.38–0.74) 0.0001 0.59 (0.42–0.82) 0.2217 0.94 (0.68–1.31) 0.7137
  75–84 years 0.87 (0.66–1.15) 0.3373 0.89 (0.67–1.17) 0.0015 0.85 (0.64–1.13) 0.2630
  85 and older 0.91 (0.69–1.12) 0.4868 0.95 (0.72–1.25) 0.6917 0.94 (0.71–1.25) 0.6753
Race, white 0.91 (0.75–1.12) 0.3847 0.91 (0.74–1.12) 0.3631 1.00 (0.81–1.23) 0.9954
Poverty statusc 1.18 (1.01–1.38) 0.0386 1.18 (1.01–1.39) 0.0386 1.18 (1.00–1.38) 0.0501
Currently married 1.10 (0.91–1.34) 0.3043 1.04 (0.88–1.29) 0.5309 1.04 (0.86–1.26) 0.6834
High school education 0.93 (0.80–1.09) 0.3657 0.94 (0.80–1.09) 0.3990 0.94 (0.80–1.10) 0.4316
Urban residence 1.02 (0.86–1.21) 0.8211 1.03 (0.87–1.22) 0.6960 0.84 (0.71–0.99) 0.0478
Yeard
 2000 1.18 (0.95–1.47) 0.1312 1.17 (0.94–1.46) 0.1536 1.09 (0.88–1.37) 0.4323
 2001 1.19 (0.99–1.56) 0.0521 1.28 (1.02–1.60) 0.0315 1.16 (0.93–1.46) 0.1935
 2002 1.19 (0.96–1.47) 0.1072 1.21 (0.97–1.50) 0.0806 0.94 (0.76–1.17) 0.5913
BMI groupe
 Underweight 1.10 (0.90–1.34) 0.3629 1.20 (0.98–1.47) 0.0816
 Overweight 0.94 (0.77–1.14) 0.5108 0.88 (0.73–1.08) 0.2164
 Obese 1.20 (0.96–1.51) 0.1103 1.06 (0.84–1.33) 0.2164
ADL impairment 1.04 (0.86–1.26) 0.6873 1.23 (1.01–1.49) 0.0425
Supplemental health insurance 0.90 (0.73–1.10) 0.2936 0.66 (0.54–0.82) 0.0001
Supplemental drug coverage 0.90 (0.75–1.08) 0.2415 0.86 (0.71–1.03) 0.0941
Fair or poor self-rated healthd 1.47 (1.24–1.74) <0.0001 1.14 (0.96–1.35) 0.1235
Physical restraint order 0.90 (0.86–1.18) 0.4342 1.08 (0.82–1.43) 0.5871
Number of reported physical
conditions
1.24 (1.22–1.26) <0.0001
Reported psychiatric diagnoses
 Anxiety disorder 1.00 (0.77–1.33) 0.9588
 Mood disorder 0.78 (0.65–0.93) 0.0070
 Schizophrenia 0.98 (0.69–1.41) 0.0079
Signs and symptoms
 Delirium 1.14 (0.82–1.60) 0.0468
 Delusions 0.98 (0.83–1.16) 0.6066
Number administered
psychotherapeutic drug
classesf
1.03 (0.96–1.11) 0.4436
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Variable Model I (Unadjusted)
Model II (Model I +
Demographics,
Socioeconomic Status)
Model III (Model II +
Health Variables)
Model IV (Model III +
Disease and Drug
Burden)
Duplicative antipsychotic use 1.17 (0.75–1.83) 0.4918
II. Mortality
 Antipsychotic use 0.67 (0.57–0.80) <0.0001 0.83 (0.69–0.98) 0.0328 0.78 (0.65–0.93) 0.0058 0.83 (0.69–1.00) 0.0537
 Gender–male 1.36 (1.15–1.62) 0.0004 1.36 (1.15–1.62) 0.0004 1.34 (1.13–1.59) 0.0010
 Age groupb
  <65 years 0.18 (0.10–0.31) <0.0001 0.21 (0.12–0.36) <0.0001 0.23 (0.13–0.40) <0.0001
  75–84 years 1.38 (0.99–1.93) 0.0568 1.38 (0.99–1.93) 0.0563 1.33 (0.95–1.86) 0.0978
  85 and older 1.89 (1.36–2.61) 0.0001 1.82 (1.32–2.53) 0.0003 1.70 (1.22–2.36) 0.0016
Race, white 1.09 (0.87–1.37) 0.4510 1.04 (0.82–1.30) 0.7594 1.07 (0.85–1.35) 0.5707
Poverty status 0.93 (0.79–1.10) 0.3858 1.06 (0.89–1.26) 0.5020 1.04 (0.87–1.23) 0.6805
Currently married 1.07 (0.89–1.30) 0.4580 1.04 (0.86–1.26) 0.6739 1.02 (0.84–1.23) 0.8610
High school education 1.15 (0.98–1.34) 0.0846 1.11 (0.94–1.29) 0.2143 1.08 (0.92–1.26) 0.3652
Urban residencec 0.94 (0.80–1.11) 0.4487 0.98 (0.83–1.15) 0.7919 0.97 (0.83–1.1) 0.75465
Yeard
 2000 1.11 (0.91–1.37) 0.3094 1.13 (0.91–1.39) 0.2765 1.17 (0.95–1.44) 0.1520
 2001 0.91 (0.73–1.14) 0.4295 0.82 (0.77–1.23) 0.2765 1.00 (0.80–1.26) 0.9771
 2002 0.64 (0.51–0.80) <0.0001 0.69 (0.55–0.87) 0.0016 0.72 (0.57–0.9) 0.0062
BMI groupe
 Underweight 1.61 (1.34–1.93) <0.0001 1.62 (1.35–1.94) <0.0001
 Overweight 0.82 (0.66–1.01) 0.0628 0.83 (0.67–1.03) 0.0888
 Obese 0.86 (0.64–1.15) 0.2983 0.99 (0.74–1.31) 0.4684
ADL impairment 1.06 (0.87–1.29) 0.5953 0.97 (0.79–1.20) 0.8045
Supplemental health insurance 0.37 (0.31–0.44) <0.0001 0.36 (0.30–0.44) <0.0001
Supplemental drug coverage 1.06 (0.87–1.30) 0.5523 1.06 (0.87–1.29) 0.5859
Poor/fair self-rated healthd 1.42 (1.19–1.69) <0.0001 1.43 (1.20–1.70) <0.0001
Physical restraint order 1.23 (0.96–1.59) 0.0996 1.18 (0.92–1.53) 0.3100
Number of reported physical
conditions
1.00 (1.00–1.02) 0.7941
Reported psychiatric conditions
 Anxiety disorder 0.87 (0.65–1.17) 0.3535
 Mood disorder 0.96 (0.79–1.16) 0.6435
 Schizophrenia 0.38 (0.18–0.81) 0.0121
Signs and symptoms
 Delirium 1.39 (1.17–1.64) 0.0001
 Delusions 1.02 (0.71–1.47) 0.9315
Number administered
psychotherapeutic drug
classesg
0.95 (0.87–1.03) 0.2392
Duplicative antipsychotic use 0.44 (0.18–1.09) 0.0760
a
For this study, we used a survival analysis (Cox proportional hazard model). This method of analysis estimates and associated p values are based
upon a df of 1 for all parameters in the model.
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b65–74 years is the reference group.
c100% of federal poverty level (FPL) versus those greater than 100% FPL.
dGood, very good, or excellent health is the reference.
e
Desirable weight category is the reference group.
f1999 is the reference year.
gAntidepressant, mood stabilizer, sedative/hypnotic, anxiolytic, stimulant, and skeletal muscle relaxant. Excludes antipsychotic medications and
prn orders.
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 su
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na
ly
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 pr
op
ort
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 d
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